Taro Pharmaceuticals U.S.A., Inc. v. Perrigo UK FINCO Limited Partnership
1:15-cv-00859
Overview
Parties
Defendant
Perrigo UK FINCO Limited Partnership NPE (University / Research)
Represented By
2 Attorneys ListedPhillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St
Phillips, Goldman, McLaughlin & Hall, P.A.
Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street
Plaintiff
Taro Pharmaceuticals North America, Inc. Operating Company
Represented By
1 Attorneys ListedHeyman Enerio Gattuso & Hirzel LLP
300 Delaware Avenue, Suite 200, Wilmington, DE 19801
Taro Pharmaceuticals U.S.A., Inc. Operating Company
Represented By
4 Attorneys ListedHeyman Enerio Gattuso & Hirzel LLP
300 Delaware Avenue, Suite 200, Wilmington, DE 19801
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 4 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| π PCT International (WIPO) | PCT World Application | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
Taro Pharmaceuticals USA Inc. v. Perrigo Israel Pharmaceuticals Ltd.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8277780
Stable liquid desoximethasone compositions with reduced oxidized impurity
|
Filed: 2006-05-26
Issued: 2012-10-02
|
Active (1.4 yrs remaining)
+698d PTA
Expires: 2028-04-23
|
|
|
US8715624
Stable liquid desoximethasone compositions with reduced oxidized impurity
|
Filed: 2012-09-06
Issued: 2014-05-06
|
Active (5.8 yrs remaining)
Expires: 2032-09-06
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term; injunctive relief viable.
High PTA (+698 days) / In re Cellect scrutiny applies.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).